RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. A peripheral stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy. When the healthy stem cells are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Giving combination chemotherapy together with imatinib mesylate and peripheral stem cell transplant may be an effective treatment for acute lymphoblastic leukemia. Nevertheless, in the last few years GIMEMA has pubblished a paper in which 100% of Ph+ ALL patients reach HCR only with Imatinib, without any chemiotherapy. Thus, this treatment will be implemented in patients pertaining to this category.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
470
Ospedale Civile Alessandria
Alessandria, Italy
Ospedale Torrette University Ancona
Ancona, Italy
Ospedale S. Donato
Arezzo, Italy
Dipartimento Area Medica - Presidio Ospedaliero "C. e G.Mazzoni"
Ascoli Piceno, Italy
S.G. Moscati Hospital
Avellino, Italy
Universita Degli Studi di Bari
Percentage of Participants Reaching Disease Free Survival
Time frame: At 60 months
Number of Patients Reaching Complete Hematological Response After Induction Therapy
Time frame: At the end of induction, day +50
Percentage of Participants Reaching Overall Survival
Overall survival from diagnosis
Time frame: At 60 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Bari, Italy
University of Bologna Medical School
Bologna, Italy
Spedali Civili di Brescia
Brescia, Italy
A. Perrino Hospital
Brindisi, Italy
Ospedale Binaghi
Cagliari, Italy
...and 56 more locations